Skip to main content
Search form
Search
Medicines for Malaria Venture
Developing antimalarials to save lives
Research & Development
MMV-supported projects
R&D areas of work
Next-generation medicines
Products for key populations
Working with regulators
Information for scientists
Malaria online course
Global health compound design webinars
Call for proposals
TPPs & TCPs
Learning resources for scientists
Project of the year award
Computational chemistry
R&D challenges
Access
Products & projects
Product availability maps
Areas of work
Supporting introduction
Enhancing reach
Informing R&D
Gathering market intelligence
Tool Kits
Injectable Artesunate tool kit
Artesunate rectal capsules tool kit
Seasonal Malaria Chemoprevention tool kit
Access challenges
Partnering
The PDP model
Our partner network
Our donors
Current donors
Past donors
Donate to MMV
Socially responsible agreements
Our clinical centre partners
Our impact
Milestones
Real life stories
Better medicines for children
Gender equity
Global health security
Malaria and COVID-19
Tackling antimicrobial resistance
About us
What we do
An overview of our work
Our strategic focus
Our history
People & governance
Staff bios
Staff interviews
Board of Directors
MMV North America Board
Expert Scientific Advisory Committee
Access & Product Management Advisory Committee
Global Safety Board
Work with us
Jobs
RFPs/RFIs
Policies
Diversity at MMV
Funding and expenditure
FAQs
Contact us
Malaria & medicines
Definitions and symptoms
Five species
Parasite lifecycle
Malaria facts & figures
Malaria treatment
History of antimalarials
Newsroom
News & Press Releases
Audio
Media interviews
Speaking of Malaria podcast
Films
Infographics
Interviews
Image slideshows
Publications
Events
MMV Open
Malaria
Libre
About Malaria
Libre
Participate in Malaria
Libre
Malaria
Libre
data repository
MMVSola
About MMVSola
Pandemic Response Box
About the Pandemic Response Box
Request the Pandemic Response Box
Supporting information
Terms & conditions
COVID Box
About the COVID Box
Supporting information
COVID Box terms and conditions
Archived projects
Pathogen Box
Malaria Box
MMV Open Team
Contact us
Home
Newsroom
Press releases
Press releases
Filter
All
R&D
Donors
General
Open source
Partner
Access & product management
All
R&D
Donors
General
Open source
Partner
Access & product management
157 found
Japan’s First PPP to Spearhead Innovation in Global Health
08 Apr 2013
Open access initiative reveals drug hits for deadly neglected tropical diseases
13 Nov 2012
African antimalarial research bears first fruit
28 Aug 2012
MMV assesses risk of resistance
22 Aug 2012
Delivery of child-friendly antimalarial hits the 100 million mark
22 Feb 2012
One step closer to blocking the transmission of malaria
21 Feb 2012
Pyramax® receives positive opinion from the EMA
20 Feb 2012
MMV and SCYNEXIS offer 400 active compounds for neglected disease drug research at no cost
19 Dec 2011
New generation of lifesaving medicines and vaccines for the world’s poor now at risk
08 Dec 2011
Marketing authorization for Eurartesim® announced at media roundtable
30 Nov 2011
New dual-acting antimalarial compounds discovered
17 Nov 2011
Partnership reaches important milestone
14 Nov 2011
Patient screening underway for Pyramax® sub-study in Sotuba, Mali
09 Nov 2011
Antimalarial drug discovery urgently needs prioritised 5-year plan to avoid missing opportunities
11 Oct 2011
Molecule moves through preclinical development in record time
02 Sep 2011
Artemisinin’s key impurities identified and made available as reference standards
20 Jun 2011
MMV supports new technique to measure quality of artemisinin
06 Jun 2011
MMV participates in Asia Pacific efforts to eliminate malaria
25 May 2011
Sanofi-aventis and MMV join forces to develop innovative malaria drugs
05 May 2011
"SMS for Life" rolled-out nationwide in the United Republic of Tanzania
18 Apr 2011
Anacor Pharmaceuticals and MMV sign agreement to pursue promising compound for malaria
18 Mar 2011
Jomaa Pharma and MMV to co-develop novel malaria treatment based on fosmidomycin
15 Feb 2011
Single-dose cure for malaria edges closer to the clinic
08 Feb 2011
International status granted to three not-for-profit organizations in Switzerland
09 Dec 2010
MMV, Novartis and partners discover novel antimalarial drug candidate
03 Sep 2010
MMV becomes first PDP to make its IP freely available for neglected diseases research
16 Aug 2010
MMV to screen Ferrer compound library
15 Jul 2010
AstraZeneca and MMV join efforts in the fight against malaria
28 Jun 2010
Data from MMV-supported research now in the public domain
20 May 2010
MMV and Anacor join hands in hunt for new antimalarial compounds
26 Apr 2010
MMV supports trials of a new preventive treatment option for pregnant women
23 Apr 2010
Pyramax® submitted to EMA for regulatory approval
08 Apr 2010
MMV’s Project of the Year for 2009 goes to Spiroindolones
15 Mar 2010
MMV-GSK compound library screening to be made public
20 Jan 2010
MMV 10th Anniversary Seminars: presentations and video clips
04 Dec 2009
MMV’s President and CEO to step down in 2010
23 Nov 2009
MMV and sanofi-aventis launch ambitious antimalarial monitoring programme
19 Nov 2009
MMV receives $115 million from Gates Foundation
19 Oct 2009
MMV and Treague take development of (+) Mefloquine into Phase I
10 Jul 2009
Dihydroartemisinin-piperaquine submitted to EMEA for regulatory approval
06 Jul 2009
Pfizer and MMV advancing international research efforts in the fight against malaria
22 Apr 2009
MMV and Merck & Co. to develop promising antimalarial compound
18 Mar 2009
MMV and Novartis launch Coartem®
Dispersible
20 Feb 2009
MMV and Novartis launch Coartem®
Dispersible
in Africa
15 Feb 2009
Unique collaboration launches a new malaria medicine to save millions of children
27 Jan 2009
First-ever comprehensive report on the antimalarials market in Uganda shows how understanding markets can help improve access to medicines
05 Nov 2008
MMV signs MOU with sanofi-aventis
22 Oct 2008
Unforgettable launch of MMV-MOH Uganda pilot
22 Sep 2008
Genzyme Corporation and MMV Announce New Collaboration with Advinus Therapeutics to Accelerate Discovery of Novel Therapies for Malaria
26 Aug 2008
Spain becomes a major government funder of MMV
31 May 2008
Dacart development halted based on Phase III results
29 Feb 2008
MoH - MMV: Bold intervention being designed in Uganda to deliver subsidized effective antimalarials
01 Oct 2007
US NIH grants MMV over USD 5 mn for malaria research
06 Sep 2007
Start of Phase II trial of intravenous artesunate for children with severe malaria
29 Aug 2007
Uganda and MMV explore innovative ways to give patients access to life-saving antimalarials
09 May 2007
Pivotal clinical trials launched for new artemisinin-based malaria drug combination
25 Jan 2007
Malaria Map: New Tool for Malaria Control
06 Dec 2006
Medicines for Malaria Venture, Higher Colleges of Technology and Global Medical Forum Foundation Collaborate on Innovative Abu Dhabi Bio City Research Initiative to Tackle Malaria
18 Oct 2006
MMV announces a commitment of US$50 million to advance malaria research at President Clinton’s Global Initiative
21 Sep 2006
Pivotal Studies Begin for CDA in sub-Saharan Africa
25 Jul 2006
Pages
« first
‹ previous
1
2
3
next ›
last »